Specifically, the levels of S100A4 expression have been identified as an independent prognostic indicator of glioma patient survival, the worse prognosis being associated with up-regulated S100A4 expression in patients with glioblastoma of the mesenchymal molecular subgroup (Chow et al., 2017). The gene discussed is S100A4; the disease is central nervous system cancer.